Selected memory T cells infused post-haploidentical hematopoietic stem cell transplantation persist and hyperexpand
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide is a curative treatment for many hematological malignancies, yet a majority of patients still suffers from recurrent infections. Post-transplant infusion of memory T-cells could potentially enhance immunological protection without increasing the risk of eliciting acute graft-versus-host disease, which is mainly induced by naïve T-cells. Here, we performed longitudinal analysis of the lymphocyte compartment in 19 patients who underwent haplo-HSCT previously enrolled in a phase II prospective clinical trial (www.clinicaltrials.gov as #NCT04687982), in which they received post-transplant CD45RA-depleted donor lymphocyte infusions (DLI). T-cell receptor sequencing analysis showed that, surprisingly, CD45RA-depleted DLI do not increase T-cell clonal diversity, but lead to prominent expansion of a selected number of infused memory T-cell clones, suggesting recruitment of these cells in the immune response. Pathogen-specific memory T-cells, including cytomegalovirus (CMV)-specific cells, were engrafted and were able to persist for at least 1 month. Deep immunophenotyping revealed strong polyfunctional effector CMV-specific T-cell responses in the majority of patients, with their expansion correlating with the frequency of CMV-specific cells in the donor. These findings provide a rationale behind the suggested improved protection against viral infections in patients receiving CD45RA-depleted DLI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Blood advances - 7(2023), 14 vom: 25. Juli, Seite 3458-3468 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van Beek, Jasper J P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 17.07.2023 Date Revised 24.07.2023 published: Print ClinicalTrials.gov: NCT04687982 Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2022007735 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349815917 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349815917 | ||
| 003 | DE-627 | ||
| 005 | 20231226043530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2022007735 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM349815917 | ||
| 035 | |a (NLM)36469095 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van Beek, Jasper J P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Selected memory T cells infused post-haploidentical hematopoietic stem cell transplantation persist and hyperexpand |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.07.2023 | ||
| 500 | |a Date Revised 24.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT04687982 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide is a curative treatment for many hematological malignancies, yet a majority of patients still suffers from recurrent infections. Post-transplant infusion of memory T-cells could potentially enhance immunological protection without increasing the risk of eliciting acute graft-versus-host disease, which is mainly induced by naïve T-cells. Here, we performed longitudinal analysis of the lymphocyte compartment in 19 patients who underwent haplo-HSCT previously enrolled in a phase II prospective clinical trial (www.clinicaltrials.gov as #NCT04687982), in which they received post-transplant CD45RA-depleted donor lymphocyte infusions (DLI). T-cell receptor sequencing analysis showed that, surprisingly, CD45RA-depleted DLI do not increase T-cell clonal diversity, but lead to prominent expansion of a selected number of infused memory T-cell clones, suggesting recruitment of these cells in the immune response. Pathogen-specific memory T-cells, including cytomegalovirus (CMV)-specific cells, were engrafted and were able to persist for at least 1 month. Deep immunophenotyping revealed strong polyfunctional effector CMV-specific T-cell responses in the majority of patients, with their expansion correlating with the frequency of CMV-specific cells in the donor. These findings provide a rationale behind the suggested improved protection against viral infections in patients receiving CD45RA-depleted DLI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 700 | 1 | |a Puccio, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Di Vito, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a De Paoli, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Zaghi, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Calvi, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Scarpa, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Peano, Clelia |e verfasserin |4 aut | |
| 700 | 1 | |a Basso, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Cibella, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a De Philippis, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Sarina, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Timofeeva, Inna |e verfasserin |4 aut | |
| 700 | 1 | |a Capizzuto, Rossana |e verfasserin |4 aut | |
| 700 | 1 | |a Mannina, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Mineri, Rossana |e verfasserin |4 aut | |
| 700 | 1 | |a Mariotti, Jacopo |e verfasserin |4 aut | |
| 700 | 1 | |a Crocchiolo, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a Castagna, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Bramanti, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Mavilio, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Lugli, Enrico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 7(2023), 14 vom: 25. Juli, Seite 3458-3468 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:14 |g day:25 |g month:07 |g pages:3458-3468 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2022007735 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 14 |b 25 |c 07 |h 3458-3468 | ||